US pharma major Merck (NYSE: MRK) is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed ...
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...
Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
13d
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Pharmaceutical Technology on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
At JPM26, MSD noted it was awaiting 20 potential launches and 80 late-stage readouts, which it claims could double $35bn ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already ...
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...
With that as the backdrop, here's a rundown of three dividend stocks to buy with plans to only hold them for the next 10 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback